Login to Your Account

Other News To Note

Wednesday, September 19, 2012
• Critical Outcome Technologies Inc., of London, Ontario, said it started the final series of toxicity experiments in two animal species for lead oncology compound COTI-2, a small molecule designed to act by inhibiting Akt/protein kinase B phosphorylation. The completion of those experiments represents the final of three major risk reduction studies needed to make COTI-2 an investigational new drug application-ready compound.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription